Best of ASTRO® 2024: Lung Cancer Updates – Dr. Emma Dunne
OR
Chair
Dr. Paris-Ann Ingledew
Dr. Joanne Alfieri
Panelists
Dr. Emma Dunne
Studies/trials discussed:
- 30 Gy vs. 45 Gy Consolidative Thoracic Radiation (cTRT) for Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Multicenter, Randomized, Phase 3 Trial
- Stereotactic Ablative Radiotherapy for Oligo-Progressive Cancers: Results of the Randomized Phase II STOP Trial
- Assessment of Precision Irradiation in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease (ASPIRE-ILD)
- Circulating Tumor DNA for Early Risk Stratification of Oligometastatic Lung Cancer
- Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer.
- Is consolidative thoracic radiotherapy of extensive-stage small cell lung cancer still beneficial in the era of immunotherapy? A retrospective analysis
- Safety and Efficacy Analysis of Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Treated with SHR-1316 Plus Chemotherapy and Sequential Chest Radiotherapy as First-Line Therapy from a Phase II Trial
- Thoracic Radiotherapy Improves the Outcomes of Extensive Stage Small-Cell Lung Cancer Patients Receiving First-Line Immunotherapy: A Multicenter Retrospective Analysis
- Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review
- Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease (RESPIRE-ILD)
- Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
- SBRT for oligoprogressive disease: using the evidence to maximise the benefits
- HALT Trial
- SUPPRESS-NSCLC
- LU002
- Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer
